This coronavirus vaccine maker entered the market behind rivals.
A potentially very lucrative arrangement with a peer doesn't necessarily make the company a buy.
These two healthcare stocks may be deeply undervalued.
Novavax shares have soared and plummeted in recent years.
Moderate success regarding a new licensing deal with Sanofi could make the troubled vaccine stock a top performer.
A cloud of doubt hanging over the company just gave way to some sunshine.
June S&P 500 E-Mini futures (ESM24) are up +0.40%, and June Nasdaq 100 E-Mini futures (NQM24) are up +0.44% this morning after three major U.S. benchmark indices ended the regular session in the green...
High-water price targets from a trio of Wall Street pundits imply three diminutive companies can skyrocket 223% to 557%.